{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:10:06Z","timestamp":1793729406661,"version":"4.6.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Following the introduction of sugammadex to the US clinical practice, scarce data are available to understand its utilization patterns. This study aimed to characterize patient, procedure, and provider factors associated with sugammadex administration in US patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This retrospective observational study was conducted across 24 Multicenter Perioperative Outcomes Group institutions in the United States with sugammadex on formulary at the time of the study. All American Society of Anesthesiologists (ASA) physical status I\u2013IV adults undergoing noncardiac surgery from 2014 to 2018 receiving neuromuscular blockade (NMB) were eligible. The study established 3 periods based on the date of first documented sugammadex use at each institution: the presugammadex period, 0- to 6-month transitional period, and 6+ months postsugammadex period. The primary outcome was reversal using sugammadex during the postsugammadex period\u2014defined as 6 months after sugammadex was first utilized at each institution. A multivariable mixed-effects logistic regression model controlling for institution was developed to assess patient, procedure, and provider factors associated with sugammadex administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>A total of 934,798 cases met inclusion criteria. Following the 6-month transitional period, sugammadex was used on average in 40.0% (95% confidence interval [CI], 39.8\u201340.2) of cases receiving NMB. Multivariable analysis demonstrated sugammadex use to be associated with train-of-four count of 0\u20131 (adjusted odds ratio = 4.06; 95% CI, 33.83\u20134.31) or 2 (2.45; 2.29\u20132.62) vs 3\u20134 twitches before reversal; the amount of NMB administered (3.01; 2.88\u20133.16) for the highest effective dose 95 quartile compared to the lowest quartile; advanced age (1.83; 1.71\u20131.95) compared to age &lt;41; male sex (1.36; 1.32\u20131.39) compared to female sex; major thoracic surgery (1.26; 1.13\u20131.39); congestive heart failure (1.17, 1.07\u20131.28); and ASA III or IV (1.13; 1.10\u20131.16) versus ASA I or II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Our data demonstrate broad early clinical adoption of sugammadex following Food and Drug Administration approval. Sugammadex is used preferentially in cases with higher degrees of NMB before reversal and in patients with greater burden of comorbidities and known risk factors for residual blockade or pulmonary complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000005080","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T14:02:36Z","timestamp":1596204156000},"page":"1510-1519","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["Utilization Patterns of Perioperative Neuromuscular Blockade Reversal in the United States: A Retrospective Observational Study From the Multicenter Perioperative Outcomes Group"],"prefix":"10.1213","volume":"131","author":[{"given":"Timur Z.","family":"Dubovoy","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Saager","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Colquhoun","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Mathis","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kapeles","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Medical College of Wisconsin, Wauwatosa, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Mentz","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Kheterpal","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle T.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"R1-20250227","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1213\/ANE.0000000000000757","article-title":"The RECITE Study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade.","volume":"121","author":"Fortier","year":"2015","journal-title":"Anesth Analg"},{"key":"R2-20250227","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jclinane.2018.12.042","article-title":"Incidence, risk factors, and consequences of residual neuromuscular block in the United States: the prospective, observational, multicenter RECITE-US study.","volume":"55","author":"Saager","year":"2019","journal-title":"J Clin Anesth"},{"key":"R3-20250227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2015.1103213","article-title":"Incidence of postoperative residual neuromuscular blockade after general anesthesia: a prospective, multicenter, anesthetist-blind, observational study.","volume":"32","author":"Yu","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"R4-20250227","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1399-6576.1997.tb04851.x","article-title":"Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium.","volume":"41","author":"Berg","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"R5-20250227","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/ALN.0b013e3182715b80","article-title":"Residual neuromuscular blockade affects postoperative pulmonary function.","volume":"117","author":"Kumar","year":"2012","journal-title":"Anesthesiology"},{"key":"R6-20250227","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1213\/ane.0b013e31816d1268","article-title":"Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit.","volume":"107","author":"Murphy","year":"2008","journal-title":"Anesth Analg"},{"key":"R7-20250227","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ALN.0b013e318182af3b","article-title":"Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit.","volume":"109","author":"Murphy","year":"2008","journal-title":"Anesthesiology"},{"key":"R8-20250227","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s40140-018-0265-6","article-title":"Sugammadex: appropriate use in the context of budgetary constraints.","volume":"8","author":"Cammu","year":"2018","journal-title":"Curr Anesthesiol Rep"},{"key":"R9-20250227","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CEOR.S100921","article-title":"Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center.","volume":"8","author":"Carron","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"R10-20250227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12871-017-0348-9","article-title":"Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.","volume":"17","author":"Aouad","year":"2017","journal-title":"BMC Anesthesiol"},{"key":"R11-20250227","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/bja\/aev104","article-title":"Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.","volume":"115","author":"Brueckmann","year":"2015","journal-title":"Br J Anaesth"},{"key":"R12-20250227","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1213\/ANE.0b013e3181c3be3c","article-title":"A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.","volume":"110","author":"Duvaldestin","year":"2010","journal-title":"Anesth Analg"},{"key":"R13-20250227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","article-title":"Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies.","volume":"41","author":"Herring","year":"2017","journal-title":"J Clin Anesth"},{"key":"R14-20250227","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/bja\/aex171","article-title":"Using a worldwide in-app survey to explore sugammadex usage patterns: a prospective observational study.","volume":"119","author":"O\u2019Reilly-Shah","year":"2017","journal-title":"Br J Anaesth"},{"key":"R15-20250227","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0310057X1304100316","article-title":"A survey of the management of neuromuscular blockade monitoring in Australia and New Zealand.","volume":"41","author":"Phillips","year":"2013","journal-title":"Anaesth Intensive Care"},{"key":"R16-20250227","first-page":"45","article-title":"International survey of neuromuscular monitoring in two European countries: a questionnaire study among Hungarian and Romanian anaesthesiologists.","volume":"26","author":"Pongr\u00e1cz","year":"2019","journal-title":"Rom J Anaesth Intensive Care"},{"key":"R17-20250227","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0000000000003256","article-title":"Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis.","volume":"132","author":"Kheterpal","year":"2020","journal-title":"Anesthesiology"},{"key":"R18-20250227","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12871-018-0605-6","article-title":"Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction.","volume":"18","author":"de Boer","year":"2018","journal-title":"BMC Anesthesiol"},{"key":"R19-20250227","first-page":"e63066","article-title":"Unrestricted and restricted access to sugammadex and side effect profile in a teaching hospital centre for year 2014- database audit study.","volume":"8","author":"Kadam","year":"2018","journal-title":"Anesth Pain Med"},{"key":"R20-20250227","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R22-20250227","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R24-20250227","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/bjaceaccp\/mkh002","article-title":"Pharmacology of neuromuscular blocking drugs.","volume":"4","author":"Appiah-Ankam","year":"2004","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"key":"R25-20250227","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.anclin.2011.06.002","article-title":"Clinical research using an information system: the multicenter perioperative outcomes group.","volume":"29","author":"Kheterpal","year":"2011","journal-title":"Anesthesiol Clin"},{"key":"R26-20250227","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/ALN.0b013e318293065c","article-title":"Development and validation of a score for prediction of postoperative respiratory complications.","volume":"118","author":"Brueckmann","year":"2013","journal-title":"Anesthesiology"},{"key":"R27-20250227","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0310057X1204000218","article-title":"The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital.","volume":"40","author":"Watts","year":"2012","journal-title":"Anaesth Intensive Care"},{"key":"R28-20250227","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12871-017-0429-9","article-title":"Preparing for the unexpected: special considerations and complications after sugammadex administration.","volume":"17","author":"Iwasaki","year":"2017","journal-title":"BMC Anesthesiol"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:35:37Z","timestamp":1786113337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000005080","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}